Trial · NCT07911254
Comparative Effects of Dynamic Cupping and Facilitated Positional Release in Cervicogenic Headache
NCT07911254, Not applicable, Not yet recruiting, University of Management and Technology Lahore
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Effects of Dynamic Cupping and Facilitated Positional Release in Cervicogenic Headache. Trials, record NCT07911254. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911254
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Effects of Dynamic Cupping and Facilitated Positional Release in Cervicogenic Headache
- NCT number
- NCT07911254
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 41 participants, estimated
- Lead sponsor
- University of Management and Technology Lahore
- Conditions
- Cervicogenic Headache
- Interventions
- Dynamic Cupping, Facilitated Positional Release technique
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Numeric Pain Rating Scale | Baseline and after 4 weeks | The patient is asked to rate their pain by selecting a value on the scale. An 11-point numerical rating scale is used, where "0" indicates no pain and "10" represents the worst pain imaginable at the time of assessment. (27) |
| Primary | Headache Impact Test-6 (HIT-6) | Baseline and after 4 weeks | The HIT-6 is a six-item questionnaire designed to assess the impact of headaches. Each item is rated on a five-point Likert scale, with responses scored as never (6), rarely (8), sometimes (10), very often (11), and always (13). The scale scores can range between 36 and 78. A score of ≤49 indicates no impact (Grade I), 50-55 represents moderate impact (Grade II), 56-59 indicates significant impact (Grade III), and a score of ≥60 signifies severe impact (Grade IV). The tool evaluates overall quality of life by examining two main domains: pain-related effects, including severity and functional limitation, and psychological and social consequences such as vitality, cognition, role performance, and social functioning. HIT-6 is widely recognized as a reliable and valid measure for assessing headache-related disability. (28) (29) |
| Primary | Universal Goniometer (UG) | Baseline and after 4 weeks | The range of motion will be measured using a universal goniometer which is a 12-inch transparent plastic model, featuring a protractor scale, two arms, and a fulcrum that has an inter-rater reliability (ICC2, 2 = 0.79 to 0.92) for cervical region. UG requires a high level of examiner proficiency and involves the use of a measurement scale, although the final position does not need to be maintained for immediate reading, as the score can be recorded after completion. The procedure depends on accurate alignment of three anatomical landmarks: the axis, the stationary arm, and the movable arm which requires precise identification of anatomical structures. (30) |
| Primary | Neck Disability Index (NDI) | Baseline and after 4 weeks | It is a self-reported questionnaire comprising 10 items used to assess the level of disability associated with neck pain. It evaluates various aspects of daily functioning, including pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleep, and recreational activities. Each item is scored from 0 to 5, with higher scores reflecting greater disability, resulting in a total possible score of 50. Based on the total score, disability is classified as no disability (0-4), mild disability (5-14), moderate disability (15-24), severe disability (25-34), and complete disability (35 or above). The NDI is a valid and reliable instrument that can be interpreted using either continuous scores or categorical disability levels. (31) |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Baseline and after 4 weeks | It is a 19-item self-report questionnaire that assesses sleep quality and sleep-related problems over the previous month. It evaluates areas such as perceived sleep quality, sleep habits, and sleep disturbances. An additional five questions completed by a bed partner may provide clinical information but are not included in scoring. PSQI scoring generates seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 (no difficulty) to 3 (severe difficulty), producing a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality, and a total score above 5 is generally considered evidence of poor sleep quality. (32) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911254
GET https://conductscience.org/api/trials/v1/NCT07911254/registered